Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00585585 · ClinicalTrials.gov registry record · Phase 2
Pilot Study of Betahistine Dihydrochloride in the Treatment of Major Depression With Atypical Features
A Phase 2 study, sponsored by University of Cincinnati.
- Terminated
- Registry status
- Phase 2
- Development phase
- 1
- Enrollment target
NCT00585585: Clinical Trial Phase 2 study, sponsored by University of Cincinnati.
NCT00585585 is a Phase 2 study that was terminated before completion, run by University of Cincinnati. The registered enrollment target is 1 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (99% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00585585, a Phase 2 study, was terminated before completion, sponsored by University of Cincinnati.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 1 participants
- Enrollment target
Study Summary
The purpose of this study is to determine a dose of the investigational drug betahistine dihydrochloride that is both well tolerated and potentially effective in treating the symptoms of atypical depression. Atypical depression is characterized by the ability of the person's mood to improve temporarily in response to positive events, as well as features such as increased appetite, increased sleep and severe fatigue.
Primary Outcome
The highest betahistine dose that is well tolerated when patients are titrated from 50 mg to a maximum 300 mg of daily divided doses.
Interventions
- DRUG betahistine dihydrochloride
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1 participants |
| Start Date | 2007-07 |
| Est. Completion | 2011-01 |
| Phase | Phase 2 |
Why NCT00585585 stopped before completion
NCT00585585 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 1 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (99% lower).
The record links to 0 conditions, and to 1 intervention - of which betahistine dihydrochloride is the first listed.
NCT00585585 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00585585 about?
NCT00585585 is a clinical study titled "Pilot Study of Betahistine Dihydrochloride in the Treatment of Major Depression With Atypical Features". The purpose of this study is to determine a dose of the investigational drug betahistine dihydrochloride that is both well tolerated and potentially effective in treating the symptoms of atypical depression. Atypical depression is characterized by the ability of the person's mood to improve temporar...
What is the current status of trial NCT00585585?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 1 participants. The study started on 2007-07. Estimated completion is 2011-01.
What interventions are being tested in trial NCT00585585?
The interventions under investigation include: betahistine dihydrochloride (DRUG).
Who is sponsoring clinical trial NCT00585585?
This trial is sponsored by University of Cincinnati, which has 245 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00585585's enrollment target sits among peer trials
1 2001st of 2000 the lowest of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia